| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 2527469 | Clinical Therapeutics | 2013 | 20 Pages |
Abstract
Although fulvestrant 500 mg was found not to be a cost-effective option at a standard UK threshold of £20,000 to £30,000 per QALY, it may be relevant to apply a higher threshold due to the poor prognosis of patients with advanced breast cancer and the limited number of hormonal treatment options available for this stage of treatment. Certain subgroups may also benefit from fulvestrant as a treatment option; however, limited data are currently available to identify these subgroups.
Related Topics
Health Sciences
Medicine and Dentistry
Medicine and Dentistry (General)
Authors
Romita MA, MSc, Shannon MSc, Mario PhD, Pauline MSc, Matthew BSc,